Jaguar Health's Posts Crofelemer Data For Chemo-Induced Diarrhea In Breast Cancer Patients
Jaguar Health Inc (NASDAQ: JAGX) announced the topline results of the investigator-initiated Phase 2 HALT-D trial evaluating crofelemer to prevent chemotherapy-induced diarrhea (CID). The trial included HER2-positive breast cancer patients being treated with trastuzumab, pertuzumab, and a taxane.
The study included 51 breast cancer patients randomly assigned to either crofelemer or control standard of care with no prophylactic antidiarrheal medications.
Findings showed that the primary endpoint, the incidence of having diarrhea for two or more days, was not statistically different for the two groups since about 70% of patients had this outcome regardless of the cycle or CID treatment group.
The crofelemer group demonstrated better outcomes compared to the control group for several key secondary endpoints.
A lower incidence of grade 2 or higher-grade diarrhea for the crofelemer group was seen than the control group during cycle 2 based on patient outcomes and investigator assessments - (9.0% vs. 33.3%) and (9.5% vs. 41.1%), respectively.
Based on patient-reported outcomes, no patients in the crofelemer group experienced grade 3 or grade 4 diarrhea during cycle 2 compared to 17.6% of patients in the control group.
Price Action: JAGX shares are up 3.10% at $1.50 during the market session on the last check Friday.
See more from Benzinga
T2 Biosystems Shares Are Rising After Exclusive Distribution Pact In Taiwan
Dermata's Aesthetic Improvement Candidate Fails To Impress - Read Why
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
